Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post
The Jakarta Post
Video Weather icon 30°C
DKI Jakarta, Indonesia
weather-icon
30°C Partly Cloudy

Dry and mostly cloudy throughout the day.

  • weather-icon

    Wed

    26℃ - 32℃

  • weather-icon

    Thu

    25℃ - 32℃

  • weather-icon

    Fri

    25℃ - 31℃

  • weather-icon

    Sat

    26℃ - 30℃

BPJS suggests doctors prescribe 'other' breast cancer drugs

  • News Desk
    News Desk

    The Jakarta Post

Jakarta | Wed, July 18, 2018 | 03:48 pm
BPJS suggests doctors prescribe 'other' breast cancer drugs The Healthcare and Social Security Agency (BPJS Kesehatan) has suggested doctors to prescribe other drugs for breast cancer patients after it removed trastuzumab from the National Formulary on Apr. 1. (Shutterstock/ESB Professional)

Following its decision to remove the breast cancer drug trastuzumab from the National Formulary, the Healthcare and Social Security Agency (BPJS Kesehatan) has suggested that doctors prescribe a different drug for patients.

“The elimination is based on the organization’s Dewan Pertimbangan Klinis,” said BPJS Kesehatan spokesman Nopie Hidayat, as quoted by kompas.com on Wednesday, referring to the BPJS Kesehatan's Clinical Advisory Board.

“The board said the drug has no medical basis to be used for patients with metastatic breast cancer […],” Nopie said.

The BPJS Kesehatan, however, declined to comment on the case of Yuniarti Tanjung, a HER2 breast cancer patient in East Jakarta. Yuniarti and her family plan to sue the agency for removing trastuzumab from its list of approved drugs.

Yuniarti was diagnosed with HER2 breast cancer on May 10. On on June 24, a doctor at East Jakarta's Persahabatan Hospital prescribed trastuzumab, along with three other drugs, for her chemotherapy treatment.

However, she did not receive the trastuzumab because the hospital said a policy issued on Apr. 1 prohibited the national health insurance program from covering the drug. 

Yuniarti would have to pay Rp 25 million (US$1,700) to obtain the medication.

The national healthcare agency would only cover trastuzumab under the National Health Insurance-Healthy Indonesia (JKN-KIS) program for breast cancer patients who were prescribed the drug before Apr. 1, so that they could complete their treatment, Nopie said.

Nopie said the agency believed the policy would not prevent breast cancer patients from receiving proper medical treatment, saying that there were many other drugs that could replace trastuzumab.

“The doctors can choose other drugs to treat breast cancer patients based on each patient’s needs,” he said. (vla)

Join the discussions